Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Apr 26

2024

[News] Hua Medicine Initiated Phase I Clinical Trial of 2nd Gen GKA in the U.S. and Completed Enrollment of First Patient

Hua Medicine (the "Company", HKEx: 2552.HK) announced that the Company has officially initiated its Phase I clinical trial of its 2nd generation glucokinase allosteric activator (2nd Gen GKA) in the United States, with the successful enrollment of the first patient.

Mar 29

2024

[NEWS] Hua Medicine Announces 2023 Annual Results

The Company has achieved a certain milestone relating to the development of dorzagliatin and received RMB800 million non-refundable milestone payment. Collective cash balance of the Company was RMB1,461 million as of December 31, 2023.

Dec 21

2023

Hua Medicine Announces Submission of Investigational New Drug Application with U.S. FDA

Hua Medicine (HKEx:2552HK) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its 2nd generation glucokinase allosteric activator (2nd Gen GKA) to initiate a Phase I randomized, double-blinded, placebo-controlled, single-dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study in subjects with Type 2 diabetes mellitus (T2D) in the United States.

Dec 13

2023

[News] Hua Medicine Announces the Inclusion of Dorzagliatin in the National Reimbursement Drug List (NRDL)

Hua Medicine (the "Company", HKEx: 2552.HK) announced today that HuaTangNing (华堂宁®) (dorzagliatin), its self-developed first-in-class glucokinase allosteric activator (GKA) for diabetes, has been successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA).

Nov 23

2023

[News] Hua Medicine to Present Research Findings at CDS 2023

Hua Medicine (HK:2552) today announced that it will present multiple research findings at the 25th Scientific Meeting of the Chinese Diabetes Society (CDS 2023).

Aug 24

2023

[News]Hua Medicine Announces 2023 Interim Results

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Aug 17

2023

New publication shines spotlight on Hua Medicine's Dorzagliatin ability to achieve diabetes remission over 52-week period

Shanghai, 17 August 2023 – Sending Type 2 diabetes into remission is now a possibility thanks to Hua Medicine's HuaTangNing1 (华堂宁®) (dorzagliatin), as reported in a new published paper based on data from a 52-week study.

Jun 26

2023

[News] Hua Medicine Announces the Potential of Dorzagliatin in Cognitive Dysfunction at ADA 2023

Hua Medicine (the "Company", HKEx stock code: 2552) today announces that multiple basic and clinical findings of HuaTangNing (华堂宁®, dorzagliatin), the Company’s global first-in-class glucokinase activator (GKA), were presented at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.

Jun 16

2023

[News] Hua Medicine will present multiple research results at the 2023 American Diabetes Association (ADA) Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that it will present multiple research results of HuaTangNing (华堂宁®, dorzagliatin), the Company’s first-in-class glucokinase activator (GKA), at the 83rd American Diabetes Association (ADA) Annual Scientific Sessions.